We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Phibro (PAHC) Down 1.1% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Phibro Animal Health (PAHC - Free Report) . Shares have lost about 1.1% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Phibro due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Phibro Animal Health Corporation before we dive into how investors and analysts have reacted as of late.
Phibro Q4 Earnings Top Estimates, Gross Margin Dips
Phibro Animal Health delivered adjusted earnings per share of 57 cents in the fourth quarter of fiscal 2025 compared with 41 cents in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate by 9.62%.
Without adjustments, GAAP earnings per share in the quarter was 42 cents compared with 2 cents in the prior-year period.
PAHC reported full-year adjusted earnings per share of $2.09, which rose 75.6% from the fiscal 2024 figure. The figure outpaced the Zacks Consensus Estimate by 2.45%.
Revenue Details
Net sales in the quarter totaled $378.7 million, up 38.6% from the year-ago quarter’s level. The figure topped the Zacks Consensus Estimate by 4.86%.
For fiscal 2025, the company reported net sales of $1.30 billion, up 27.4% from the prior-year level. The figure beat the Zacks Consensus Estimate by 1.56%.
Q4 Segmental Sales
The company conducts its operations via three segments — Animal Health, Mineral Nutrition and Performance Products.
In the fourth quarter of fiscal 2025, Animal Health’s net sales increased 53% to $292.5 million. Our model’s projection was $264.4 million.
Within the segment, net sales of medicated feed additives (MFAs) and others reflected 77% year-over-year growth, driven by incremental revenues of $94.5 million from the Zoetis MFA portfolio and increased demand for the MFAs in international regions.
Nutritional specialty product sales rose 11% due to higher sales of microbial and companion animal products.
Net vaccine sales showed a year-over-year rise of 21% due to continued growth of poultry products in Latin America and higher international demand.
Net sales in the Mineral Nutrition segment rose 3% year over year to $64.2 million, mainly due to an increase in demand for copper and trace minerals. However, the figure lagged our model’s forecast of $74.3 million.
Net sales in the Performance Products segment rose 13% to $22.1 million due to higher demand for the ingredients used in personal care products. Our model projected $20.6 million from this segment.
Q4 Margin Performance
Phibro’s fiscal fourth-quarter gross profit rose 26.2% year over year to $110 million. However, the gross margin contracted 287 basis points (bps) to 29.1% due to a 44.5% rise in the cost of goods sold.
Selling, general and administrative expenses in the reported quarter were $76.3 million, up 11.1% from the year-ago quarter’s levels. The operating profit totaled $33.7 million, an increase of 82.2% year over year. The operating margin expanded 213 bps year over year to 8.9%.
Financial Update
The company exited the fourth quarter of fiscal 2025 with cash and short-term investments of $77 million compared with $114.6 million at the end of fiscal 2024.
Cumulative net cash provided by operating activities at the end of fiscal 2025 was $80.1 million compared with $87.6 million in the year-ago period.
Fiscal 2026 Guidance
For fiscal 2026, the company expects net sales in the range of $1.43-$1.48 billion, implying 12% growth. The Zacks Consensus Estimate for the metric is pegged at $1.41 billion.
Adjusted earnings per share is expected in the band of $2.52-$2.70, which indicates a 25% increase. The Zacks Consensus Estimate stands at $2.30.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month.
The consensus estimate has shifted 21.33% due to these changes.
VGM Scores
Currently, Phibro has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock has a grade of A on the value side, putting it in the top quintile for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Phibro has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Phibro (PAHC) Down 1.1% Since Last Earnings Report?
It has been about a month since the last earnings report for Phibro Animal Health (PAHC - Free Report) . Shares have lost about 1.1% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Phibro due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Phibro Animal Health Corporation before we dive into how investors and analysts have reacted as of late.
Phibro Q4 Earnings Top Estimates, Gross Margin Dips
Phibro Animal Health delivered adjusted earnings per share of 57 cents in the fourth quarter of fiscal 2025 compared with 41 cents in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate by 9.62%.
Without adjustments, GAAP earnings per share in the quarter was 42 cents compared with 2 cents in the prior-year period.
PAHC reported full-year adjusted earnings per share of $2.09, which rose 75.6% from the fiscal 2024 figure. The figure outpaced the Zacks Consensus Estimate by 2.45%.
Revenue Details
Net sales in the quarter totaled $378.7 million, up 38.6% from the year-ago quarter’s level. The figure topped the Zacks Consensus Estimate by 4.86%.
For fiscal 2025, the company reported net sales of $1.30 billion, up 27.4% from the prior-year level. The figure beat the Zacks Consensus Estimate by 1.56%.
Q4 Segmental Sales
The company conducts its operations via three segments — Animal Health, Mineral Nutrition and Performance Products.
In the fourth quarter of fiscal 2025, Animal Health’s net sales increased 53% to $292.5 million. Our model’s projection was $264.4 million.
Within the segment, net sales of medicated feed additives (MFAs) and others reflected 77% year-over-year growth, driven by incremental revenues of $94.5 million from the Zoetis MFA portfolio and increased demand for the MFAs in international regions.
Nutritional specialty product sales rose 11% due to higher sales of microbial and companion animal products.
Net vaccine sales showed a year-over-year rise of 21% due to continued growth of poultry products in Latin America and higher international demand.
Net sales in the Mineral Nutrition segment rose 3% year over year to $64.2 million, mainly due to an increase in demand for copper and trace minerals. However, the figure lagged our model’s forecast of $74.3 million.
Net sales in the Performance Products segment rose 13% to $22.1 million due to higher demand for the ingredients used in personal care products. Our model projected $20.6 million from this segment.
Q4 Margin Performance
Phibro’s fiscal fourth-quarter gross profit rose 26.2% year over year to $110 million. However, the gross margin contracted 287 basis points (bps) to 29.1% due to a 44.5% rise in the cost of goods sold.
Selling, general and administrative expenses in the reported quarter were $76.3 million, up 11.1% from the year-ago quarter’s levels. The operating profit totaled $33.7 million, an increase of 82.2% year over year. The operating margin expanded 213 bps year over year to 8.9%.
Financial Update
The company exited the fourth quarter of fiscal 2025 with cash and short-term investments of $77 million compared with $114.6 million at the end of fiscal 2024.
Cumulative net cash provided by operating activities at the end of fiscal 2025 was $80.1 million compared with $87.6 million in the year-ago period.
Fiscal 2026 Guidance
For fiscal 2026, the company expects net sales in the range of $1.43-$1.48 billion, implying 12% growth. The Zacks Consensus Estimate for the metric is pegged at $1.41 billion.
Adjusted earnings per share is expected in the band of $2.52-$2.70, which indicates a 25% increase. The Zacks Consensus Estimate stands at $2.30.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month.
The consensus estimate has shifted 21.33% due to these changes.
VGM Scores
Currently, Phibro has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock has a grade of A on the value side, putting it in the top quintile for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Phibro has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.